CompletedNot Applicable

Vaccine Immune Recovery After Leukemia

United States89 participantsStarted 2022-09-28

Plain-language summary

This observational study aims to assess recovery of the immune system and immunity to vaccine-preventable diseases in children, adolescents, and young adults who recently completed treatment for acute lymphoblastic leukemia (ALL). Several children's hospitals in the United States are participating in the study, which will enroll up to 100 pediatric participants. The study is intended to determine the rate of infection after leukemia treatment and to inform future studies and recommendations about whether children and adolescents who have leukemia should receive additional vaccine doses or boosters after treatment.

Who can participate

Age range3 Years – 31 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Children, adolescents, and young adults diagnosed with B or T ALL at age 12 months or older * Completed ALL chemotherapy within the past three months or will complete ALL chemotherapy in the upcoming three months * Three years of age or older at time of enrollment Exclusion Criteria: * Diagnosis of infant ALL * Evidence of disease relapse * History of primary immunodeficiency (except related to Down Syndrome) * History of a stem cell transplant or cellular immunotherapy * History of prior malignancy or condition requiring chemotherapy other than for current ALL diagnosis

What they're measuring

Incident Infection Rate in Participants During the First Year Post-acute Lymphoblastic Leukemia Therapy

Timeframe: 1 year

Trial details

NCT IDNCT05622682

SponsorChildren's Hospital of Philadelphia

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2025-10-31

Results submitted2025-12-17

View on ClinicalTrials.gov More Acute Lymphoblastic Leukemia, Pediatric trials